行情

ANIX

ANIX

Anixa Biosciences Inc
NASDAQ

实时行情|Nasdaq Last Sale

3.730
+0.250
+7.18%
盘前: 3.860 +0.13 +3.49% 07:04 01/22 EST
开盘
3.510
昨收
3.480
最高
3.790
最低
3.430
成交量
7.25万
成交额
--
52周最高
5.70
52周最低
2.740
市值
7,766.31万
市盈率(TTM)
-6.2858
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ANIX 新闻

  • 谷歌CEO皮查伊:隐私是我们工作的核心
  • 新浪科技.2小时前
  • 谷歌CEO:AI或许是目前最重要的发明 比电的意义更大
  • 新浪科技.2小时前
  • 特朗普达沃斯演讲:种一万亿棵树,我们加入
  • 新浪财经-自媒体综合.2小时前
  • 霍尼韦尔:竭尽全力保障KN95口罩在春节期间持续供应
  • 澎湃新闻.3小时前

更多

所属板块

生物技术和医学研究
-0.61%
制药与医学研究
-0.39%

热门股票

名称
价格
涨跌幅

ANIX 简况

Anixa Biosciences, Inc. is a biotechnology company. The Company is developing a cancer immunotherapy program, which leverages chimeric endocrine receptor t-cell (CER-T) technology, and is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek liquid biopsy technology is a series of non-invasive blood tests for early detection of solid tumors based on the body's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. This technology enables cancer detection in its earliest stages in efforts to treat patients when the disease is curable. The Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients.
展开

Webull提供Anixa Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。